

CHARM is recruiting ng more? participants across Canada



A UHN Research Study

Cell-free DNA in Hereditary And High-Risk Malignancies (CHARM) 2:

Evaluating the Performance of a **Blood Test for Early Cancer Detection**



Interested in learning more?

Scan the QR code below to visit our website charmconsortium.ca



You can also email us at charm-research-study@uhn.ca


Please note that communication via e-mail is not secure. Please do not communicate personal sensitive information via e-mail.





What is cell-free DNA (cfDNA)?

- Deoxyribonucleic acids (DNA) is the instruction manual telling our body how to develop and function. Most DNA is found inside of our cells.
- cfDNA are short pieces of DNA that circulate freely in your blood. Most of the cfDNA in the blood comes from normal, healthy cells.
- Cancer cells can also release cfDNA into the blood. cfDNA from cancer cells looks different than cfDNA from healthy cells.
- cfDNA can be detected with a blood test.



Our CHARM team is developing an experimental blood test for early cancer detection. Our goal is to understand the performance of this experimental blood test.

What does the study involve?

CHARM will look at the cfDNA in your blood

You will provide a blood sample up to 3 times a year, for 4 years

cfDNA in your blood sample will be analyzed *

* Each study participant will be randomly assigned to the control or test group. cfDNA will only be analyzed for those assigned to the test group.

CHARM will return the results of the blood test to you

"Cancer signal detected" or "Cancer signal not detected"



The CHARM study doctor will arrange follow-up investigations

A "cancer signal detected" result is not a diagnosis. If you receive this result, the study doctor will arrange followup investigations (e.g., additional bloodwork and imaging) to confirm or rule out cancer.

Surveys

You will be asked to complete surveys over the course of this study to help us learn how this blood test may impact your wellbeing.

Who can participate?

CHARM is recruiting individuals who are at a higher risk of developing cancer. We are enrolling people who have a variant (i.e. mutation) in one of the following genes:

- BRCA1/2, PALB2 (Hereditary Breast and **Ovarian Cancer**)
- CDH1 (Hereditary Diffuse Gastric Cancer)
- MLH1, MSH2, MSH6, PMS2, EPCAM (Lynch Syndrome)
- NF1 (Neurofibromatosis Type 1)
- TP53 (Li-Fraumeni Syndrome)

Both individuals with and without a personal history of cancer are eligible. However, at the time of study enrollment, individuals must be cancer free for at least 3 years.

This experimental blood test does not replace cancer screening tests recommended by your health care provider.



www.charmconsortium.ca